Ophtesic (Anhydrous Lidocaine Hydrochloride)

Lidocaine hydrochloride, the active ingredient in Ophtesic, is a local anesthetic presented as a sterile ophthalmic solution for ocular use. It provides temporary surface anesthesia for eye examinations and minor procedures. GNH USA supplies Ophtesic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ophtesic, a lidocaine‑based ophthalmic anesthetic, provides temporary surface anesthesia for ocular procedures.

Ocular surface anesthesia: numbs the cornea and conjunctiva to facilitate painless examinations. Diagnostic eye examinations: enables comfortable slit‑lamp, tonometry or fluorescein staining procedures. Minor ocular surgery: provides local anesthesia for interventions such as foreign‑body removal or laser treatment.

Ophtesic may cause transient ocular irritation or allergic responses.

Common Side Effects: - Burning or stinging sensation at the application site - Redness of the conjunctiva - Excessive tearing - Temporary blurred vision - Mild eyelid edema - Localized itching or mild rash

Serious or Rare Side Effects: - Corneal epithelial toxicity or ulceration - Severe allergic reaction (anaphylaxis) - Persistent visual impairment - Secondary ocular infection - Significant intraocular pressure rise - Systemic lidocaine toxicity (rare with ocular use)

Before using Ophtesic, consider the following safety measures.

Allergy assessment: confirm no known hypersensitivity to lidocaine or amide anesthetics. Contact lens use: remove lenses prior to administration. Corneal integrity: avoid use on compromised corneal epithelium. Systemic absorption: limit use in patients with severe cardiac conduction disorders. Pregnancy and lactation: use only if benefit outweighs risk and after prescriber consultation. Store at room temperature: keep in original container, protect from light and moisture.

Ophtesic can interact with other medications; monitor patients accordingly.

Major Interactions (Avoid): - Systemic lidocaine‑containing products: may increase total lidocaine exposure. - Class I antiarrhythmic drugs (e.g., quinidine, procainamide): additive cardiac effects. - Beta‑blockers: potential enhanced bradycardia if systemic absorption occurs.

Moderate Interactions (Monitor Closely): - Other ophthalmic anesthetics: cumulative local effect. - Topical vasoconstrictors: may alter ocular absorption. - Alcohol‑containing eye drops: may increase irritation.